­
­
­
­

Inventi Impact - Dermatology
(Formerly Inventi Rapid/Impact: Derma)

Patent Watch

  • Peptide sequence found in Laminin 5 for treating skin impairments

    Peptide of sequence TALRIRATYGEY (SEQ ID NO: 1) present on the gamma 2 chain of Laminin 5, a pharmaceutical composition containing the peptide and to the use of the composition for treating various skin alterations. More particularly, the treatment of the alterations includes reinforcing the derma-epidermal junction and the cell-matrix and/or cell-cell adherence of epidermis and in promoting the repair of a cutaneous surface.

  • Device for the therapeutic and cosmetic photo-processing of biological tissue and method for using the same

    The present invention relates to a method and an apparatus for permanently or temporarily removing human hair, for miniaturizing the same or for changing the color thereof. This apparatus can also be used for coagulating blood vessels, veins or a selective injury of the derma collagen in order to regenerate the same. This apparatus uses one or more incandescent lamps (4) in which the radiation spectrum (34) can be modulated in order to heat slowly and efficiently the derma (17) and in order to heat locally the hair follicles (35). This apparatus also includes an optical system that converts the blue-green portion of the spectrum of the incandescent lamps (4) into a red region of the spectrum, that provides a highly efficient concentration of converted radiation from the incandescent filament (37) of the lamps (4) on the area of biological tissues to be treated, and that ensures a repeated recirculation towards the skin (17) of the radiation scattered by the same.

  • Transcutaneous bilirubin concentration measuring apparatus and a measurement data checking plate for use with the same

    Luminous fluxes from a xenon tube are introduced from one end of an optical fiber to an other end thereof and emerge therefrom. These luminous fluxes are incident of a skin of a person to be measured, and those diffused in the skin are incident on one end of an optical fiber through a first incident port and on one end of an optical fiber through a second incident port. The luminous fluxes from the one end are split by a dichroic mirror. The luminous fluxes reflected by the dichroic mirror are received by a photoelectric conversion element via a blue filter, and those having transmitted through the dichroic mirror are received by a photoelectric conversion element via a green filter. A concentration of bilirubin pigmented in fat of subcutaneous tissues can be accurately measured without being influenced by a difference in the thicknesses of epidermis and derma.

  • Apparatus for tissue treatment

    An apparatus for tissue treatment is provided, comprising a light emitter for emission of a first light beam, director for directing the first light beam towards a target area to be treated, detector for detecting at least one tissue parameter at the target area, and first light beam controller for controlling at least one parameter without interruption of the propagating light beam. The tissue parameter may be selected from the group of texture, elasticity, size and shape. The apparatus may be used for ablating a thin epidermal layer of the derma of a patient and also marks on the tissue such as marks from chloasma, liver spots, red spots, tattoos, blood vessels just below the surface, etc. as well as warts, wounds, hair follicles, etc. may be ablated or treated.

  • Method for skin rejuvenation

    A rejuvenation method includes subcutaneous implanting an inert material at the rejuvenation area. Golden threads are used as the inert material. The golden threads are implanted in subdermal space at the level of thederma inner edge. The golden threads are implanted along and/or across wrinkles and skin folds of the rejuvenation area catching skin regions behind the rejuvenation area. The golden thread input and output sites are placed in skin regions located behind the rejuvenation area. The skin is first marked with marker lines the length of which is greater than the rejuvenation area, and the inert material is implanted under these lines. The marker lines may be applied so as to intersect and to form a net. The golden thread input and output sites are placed in site of intersection of the marker lines forming the net. The golden thread is employed in conjunction with a resolving polyglycol thread. Rejuvenation is applied to skin areas on cheeks, chin, near eyes, on arms and/or thighs.

  • Variable color incoherent alignment line and cross-hair generator

    An alignment device includes an incoherent light source, a first convex lens, a mirror rod, and a second convex lens. The incoherent light source emits incoherent light that is received by the first convex lens that produces a low divergence light beam. The low divergence light beam is directed to the mirror rod that reflects the light beam to the second convex lens that focuses the light beam to a convergent light beam.

  • Device and method for attaching hair

    A fitting and a method for utilizing one or more of such fittings are described for securing supplemental hair to a person's head, along the outer surface of the person's scalp, to create an enhanced, natural appearance independent of the population and location of any natural hair on the person's head. Each fitting includes a base and a longitudinal bridge rising from the base to establish an eye providing a lateral path beneath the bridge. Each base is embedded beneath the outer surface of the person's scalp to secure the corresponding fitting at a selected strategic location on the person's head with the bridge projecting from the outer surface to provide a corresponding attachment site. Supplemental hair is juxtaposed with and secured to each bridge with a corresponding ligature passed through the eye of each corresponding bridge.

  • Structure containing wound treatment material

    According to an aspect of the present disclosure, an anvil assembly for a circular stapling apparatus, is disclosed. The anvil assembly includes an anvil head configured to support an anvil plate thereon; a shaft extending from the anvil head and configured to selectively engage a connection member of the circular stapling apparatus; an anvil plate operatively connected to the anvil head, the anvil plate defining a plurality of staple forming pockets therein; and a wound treatment material disposed in each staple forming pocket of the anvil plate. The wound treatment material is at least one of an adhesive, a sealant, a hemostat and a medicament.

  • Skin care formulations

    Disclosed are compositions and methods for treating skin comprising a chemically compatible combination of skin active ingredients comprising palmitoyl tetrapeptide-7, methylsilanol mannuronate, and Lactobacillus ferment, a chemically compatible combination of skin active ingredients comprising plant extracts from Punica granatum, Castanea sativa, Gossypium hirsutum, and Euterpe oleracea, and a dermatologically acceptable vehicle. The compositions can be substantive in that they can remain on a person's skin during sleep.

  • Methods for determining the hair follicle inductive properties of a composition

    The present invention provides a method for determining hair inductive properties of a composition comprising injecting a composition comprising dissociated dermal cells and epidermal cells into skin of a mammal and determining whether at least one hair follicle forms.

  • PARTICLES COMPRISING A BIOPOLYMER WHICH IS DEGRADABLE UNDER THE EFFECT OF AN ELECTROMAGNETIC WAVE AS EMITTED BY A SOLAR RADIATION

    The invention relates mainly to a particle comprising at least one biopolymer which is degradable under the effect of an electromagnetic wavelength, notably the wavelength of which is in the spectrum of the wavelengths emitted by the sun, this biopolymer comprising nucleosides. The invention also relates to compositions containing such particles with the aim of delivering an active principle. These particles can be used mainly in cosmetics, in dermatology, in pharmacy, in agri-food or en agro-industrials.

  • Photoprotector and/or photoimmunoprotector compositions of the skin and their uses

    The composition comprises of a component A selected from a hydroxylated derivative of benzoic acid or of cinamic acid, their esters, amides or salts, a glycoside of a hexose, and their mixtures; and a component B selected from quinic acid, shikimic acid, their alkaline metal or alkaline earth salts, their methyl esters, and mixtures of the same. This composition is suitable for protecting the skin against ultraviolet radiation coming from the sun or artificial sources, such as those used in phototherapy units and in sun tanning rooms. For application in the field of dermatology and nutrition, and, in particular, in the photoprotection of the skin and mucosa, photo-ageing and photocarcinogenesis, including protection of the immune system associated with the skin.

  • TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING A WATER-SENSITIVE ACTIVE PRINCIPLE

    A topical pharmaceutical composition including, as a pharmaceutical active agent, a water-sensitive compound in a solubilised form in a physiologically acceptable medium is described. A method for preparing such a composition, and uses thereof in dermatology are also described.

  • USE OF STEM CELLS FROM HAIR ROOT SHEATHS AND KERATINOCYTE PRECURSOR CELLS FOR THE REGENERATION OF AGED SKIN

    The present invention relates to the use of stem cells from hair root sheaths and/or keratinocyte precursor cells for the regeneration of aged but otherwise healthy and non-injured skin for the cosmetic purposes and for the prevention of skin diseases. In addition, the invention is directed to a cosmetic method for the regeneration of aged skin.

  • COLOSTRUM COMPOSITION

    The present invention relates to a composition comprising colostrum and at least one agent selected from the group of hydrocolloids, wherein said colostrum and at least one agent are bioconjugated. The bioconjugated composition has improved properties compared to colstrum compositions that are not bioconjugated with a hydrocolloid agent. The composition may be used in a variety of settings, for example for topical application for treating skin diseases and skin conditions. The present invention thus also relates to use of the composition and to a method for the preparation of the composition.

  • Novel Tricyclic Modulators of Cannabinoid Receptors

    The compounds of the invention are modulators of cannabinoid receptors CB1 or CB2. The compounds can be used for the prevention or treatment of, e.g., pain, cancer, skin diseases, weight-associated disorders, chemical addictions, psychiatric disorders, neurodegenerative disorders, bone diseases, and inflammatory diseases. The compounds of the invention can further be used to study these diseases and disorders, as well as cannabinoid receptor biology, by coupling the compounds to, e.g., imaging agents.

  • COMBINATION OF COMPOUNDS FOR TREATING OR PREVENTING SKIN DISEASES

    A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay is described.

  • METHOD AND APPARATUS FOR IMAGING TISSUE TOPOGRAPHY

    The present invention relates to an optical device for imaging and measuring characteristics of an objects surface shape, surface spectral reflectance and structure of sub-surface layers. In particular, the invention relates to imaging of topography of human skin and skin sub-surface layers and determination of concentration of skin constituents. The present invention has applications in areas such as skin care, dermatology, cosmetics, wound management and tricology. The imaging device of the invention significantly improves photometric stereo measurements by suppressing specular reflection and allows accurate determination of the surface shape. Consequently the device allows elimination of the influence of the shape and illumination conditions on spectral measurements and allows accurate measurement of skin constituents.

  • USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING DERMATITIS

    The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.

  • METHOD FOR DETERMINATION OF UNKNOWN MUTATIONS

    The present invention relates to a method of using Raman spectra to identify unknown mutations in a gene, more specifically the filaggrin gene. Specifically, the present invention relates to a method to determine if a person has a homozygous or compound heterozygous mutation in the filaggrin-gene comprising measurement of the presence of tyrosine in the skin. Preferably said measurements are performed by Rama spectrography and on the tsiie of the skin, most preferably on the palm of the hand. Further, when these measurements are taken together with measurements of the NMF content of the skin it, the present invention relates to a method of classifying atopic dermatitis.

  • TRICYCLIC INDOLE-DERIVED SPIRO DERIVATIVES AS CRTH2 MODULATORS

    The present invention relates to compounds of formula (I) for use as pharmaceutical active compounds, as well as pharmaceutical formulations containing the same, for the treatment of allergic diseases. The compounds according to Formula (I) are suitable as modulators of CRTH2. The invention provides Spiro derivatives according to Formula (I) and related formulae that are useful in the treatment and/or prevention of diseases selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, and inflammatory dermatoses such as atopic dermatitis, contact hypersensitivity, allergic contact dermatitis, chronic urticaria/chronic idiopathic/autoimmune urticaria, drag-induced exanthems (e.g., toxic epidermal necrolysis or Lyell's syndrome/Stevens-Johnson syndrome/drug hypersensitivity syndrome), photodermatosis or polymorphous light emption (e.g., photoirritant contact dermatitis, photoallergy contact dermatitis, chronic actinicdermatitis), and myositis neurodegenerative disorders such as neuropatic pain and other diseases with an inflammatory component such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD).

  • EXTERNAL USE COMPOSITION FOR SKIN

    The present disclosure provides an external use composition for skin comprising a tarajo holly leaf extract and a Japanese knotweed leaf extract, a brown algae extract and an egg shell membrane derived peptide (ESM-P) having a molecular mass of 3 kDa or higher. The composition according to the present invention can be used to treat a disease or condition of skin relating to a filaggrin metabolism anomaly, such as atopic dermatitis. The composition according to the present invention can be used specifically for the therapy of atopic dermatitis.

  • METHODS FOR INHIBITING CUTANEOUS INFLAMMATION AND HYPERPIGMENTATION

    This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treating contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.

  • Topical base and active agent-containing compositions, and methods for improving and treating skin

    The present invention provides unique, efficacious, inexpensive, safe, reliable, convenient, minimally bitter, skin protecting and penetrating, easy-to-administer base compositions and active agent-containing compositions, such as those including hydrocortisone, and related production and topical application methods, for treating the skin of mammals for a wide variety of different dermatologic conditions, disorders and diseases, such as inflammation, redness, cracking, insect bites, dryness, allergic reactions, trauma, irritant dermatitis, perleche, contact dermatitis, psoriasis, eczema, seborrheic dermatitis, acne excoriate, xerosis, eczema craquele, stasis dermatitis, disease related conditions and dryness from medications such as isotretinoin, acitretin and lipid lowering agents. This is effected by topically administering, or otherwise applying, effective amounts of the compositions thereto in forms that not only address the skin and mucosa of the mouth and lips, but also of the rest of the body and, in particular, areas where other topical balms containing hydrocortisone and other active ingredients have not been developed or marketed. Additionally, the flavoring addition to this product, and the base wherein the active ingredient(s) reside, affords a significantly better tasting, and less bitter, composition, thereby allowing a more pleasant experience and better compliance by patients. Larger sized stick formulation(s) allow for more applicability of the product, and more usefulness thereof, in various areas, and mucosal skin, of the body. The compositions include a unique formulation of FANCOL VB, Natunola Castor 1023, Finsolv TN, bees wax and, optionally, one or a plurality of plant or plant seed oils, fatty alcohols, fats and flavorings, in desirable weight percents thereof, in various forms, and preferably in the form of a solid roll-on stick present in a variety of sizes.

  • Medical Device For Healing Wounds and Skin Diseases

    The present invention discloses a medical device having a disposable member for treating dermatological diseases and topical pathogeneses. The device comprises, inter alia, at least one inner layer at least partially made of a non-woven material, being in physical contact with at least a part of the derma having the dermatological diseases; at least one external impervious and flexible layer, at least partially made of material selected from a group consisting of silicone, rubber and polymer, enveloping the inner layer; and, source of hypertonic solution wetting the inner layer such that the inner layer is continuously immersed with the hypertonic solution and a constantly hypertonic environment around the derma is maintained. The inner layer is disposable and reversibly detachable to the enveloping external layer such that frequent displacement of the inner layer is possible, topical pathogeneses are being removed and dermatological diseases are being treated.

  • Collagen For Use In The Treatment Of Skin Diseases

    The invention relates to collagen for use in the treatment of inflammatory and degenerative skin diseases and damage to the skin connected therewith, such as in particular in the treatment of psoriasis, dermatitis, neurodermitis, rosacea, urticaria (hives), pruritus (itching), skin eczema and actinic keratosis. In particular, the invention relates to freeze-dried collagen in the form of layered dressings, sheets, pads or masks for the aforementioned use.

  • Collagen For Use In The Treatment Of Skin Diseases

    The invention relates to collagen for use in the treatment of inflammatory and degenerative skin diseases and damage to the skin connected therewith, such as in particular in the treatment of psoriasis, dermatitis, neurodermitis, rosacea, urticaria (hives), pruritus (itching), skin eczema and actinic keratosis. In particular, the invention relates to freeze-dried collagen in the form of layered dressings, sheets, pads or masks for the aforementioned use.

  • TOPICAL FORMULATIONS COMPRISING A STEROID

    The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

  • ORAL COMPOSITION FOR ALLEVIATING ULTRAVIOLET IRRADIATION-INDUCED DAMAGE

    Disclosed are: an oral composition for alleviating ultraviolet irradiation-induced damage, which can be used on a daily basis and is stable and safe; and a medicinal agent; and anti-wrinkle agent and a food composition, each of which comprises the oral composition. Specifically disclosed is an oral composition for alleviating ultraviolet irradiation-induced damage, which comprises at least one compound selected from the group consisting of methionine and derivatives and/or salts thereof. The composition may be an anti-wrinkle agent, a pharmaceutical composition for treating and/or preventing skin diseases, a food composition, or a pharmaceutical composition for preventing or treating cataract. In the oral composition for alleviating ultraviolet irradiation-induced damage, methionine may be in the D-form.

  • COMPOSITION FOR ALLEVIATING ULTRAVIOLET IRRADIATION-INDUCED DAMAGE

    Disclosed are a composition for alleviating ultraviolet irradiation-induced damage, which is stable and safe and can be used on a daily basis, and a pharmaceutical composition, an external skin preparation, a food composition and a medicine for cataract, each comprising aforesaid composition for alleviating ultraviolet irradiation-induced damage. Specifically disclosed is a composition for alleviating ultraviolet irradiation-induced damage which contains one or more kinds of compounds selected from the group consisting of methionine, D-serine and derivatives and/or salts of the same. The aforesaid composition may be an external preparation for the skin, an anti-wrinkle agent, a sunscreen agent, a medicinal composition for treating and/or preventing skin diseases, a food composition or a pharmaceutical product for cataract. In the aforesaid composition for alleviating ultraviolet irradiation-induced damage, the aforesaid methionine may be D-methionine, and the aforesaid D-serine derivative may be D-cycloserine.

  • CASPASE-8 AND SKIN DISEASE

    The invention relates to the treatment or prevention of an inflammatory skin disease, disorder or condition, by modulating a protein that is normally regulated by caspase-8 in the skin or by increasing caspase-8 activity or level in the skin. Another aspect of the invention relates to methods for diagnosing an inflammatory skin disease, disorder or condition or a predisposition to develop said disease disorder or condition in an individual. Further aspects of the invention relate to methods for identifying target proteins involved in the course or pathology of an inflammatory skin disease, disorder or condition and to methods of screening a candidate compound for treating said disease, disorder or condition. In particular, the invention relates to inflammatory skin diseases such as atopic dermatitis and psoriasis.

  • COMPOSITION FOR ALLEVIATING ULTRAVIOLET RADIATION-INDUCED DAMAGE

    Disclosed are: a composition for alleviating ultraviolet irradiation-induced damage, which can be used on a daily based and is stable and safe; and a pharmaceutical preparation, a cosmetic and a food composition, each of which comprises the composition. The composition for alleviating ultraviolet irradiation-induced damage contains one or more compounds selected from the group consisting of D-glutamic acid, L-glutamic acid, D-proline, D-cystine, L-cystine, and derivatives and/or salts of the aforementioned compounds. The composition can be used as an external formulation for the skin, a cosmetic composition, an anti-wrinkle agent, a sunscreen agent, a pharmaceutical composition for treating and/or preventing skin diseases, a food composition, or a pharmaceutical composition for preventing or treating cataract.

  • COMPOSITIONS FOR PREVENTING, REDUCING OR TREATING KERATINOCYTE-MEDIATED INFLAMMATION

    The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to inhibit a heteromeric receptor comprising OSMR.beta. as a subunit, for the preparation of a composition for inhibiting the expression of inflammatory factors by the keratinocytes. In particular, the invention concerns the use of antagonists and/or expression inhibitors of OSM, IL-17, TNF.alpha., IL-31, IFN-.gamma., and/or the OSMR.beta. subunit, for the preparation of cosmetic or dermatologic compositions, especially for treating inflammatory skin diseases. Methods for obtaining in vitro or animal models of skin inflammation diseases are also disclosed. These models can be used for screening molecules to find new drugs to prevent or treat psoriasis and other dermatitis.

  • HYALURONIC ACID ESTERS, THEIR PREPARATION AND USE IN DERMATOLOGY

    New ester derivatives of hyaluronic acid with hydroxy-cinnamic acid, their rheological and anti-radical properties are used as protective agents in dermatology.

  • SKIN PHOTO INTERPRETING PROGRAM AND PROFESSIONAL & PHYSICIAN ADVISORY BOARD GUIDED DERMATOLOGY TEXT SEARCH ENGINE AND FACILITATOR OF PHYSICIAN APPOINTMENTS

    A method of providing information executed by a computer program interacting with several professionals and with a customer who has provided the photo of a person's skin, hair or nails, including the steps of: the customer acquiring at least one photo of a skin, hair or nails; the customer accessing the program on a computer; the customer subscribing to the text match service; the customer uploading to the program the photo; the customer entering an identification of the body area of which the photo was taken; the program publishing the photo and making it anonymous; the program queuing the photo for reading; a professional retrieving the photo from the queue; the professionals reading the photo and identifying the displayed skin condition; the professionals each matching the photo to two preferred stored texts describing the identified skin condition; the program publishing the photo in combination with the text; the program notifying the customer and the customer displaying the text. A preferred additional step is that of the program providing the customer with a random code to be used to expedite an appointment with a dermatologist in the customer's geographic area.

  • IMPLANT FOR SUBCUTANEOUS OR INTRADERMAL INJECTION

    The invention concerns an injection implant for filling up wrinkles, thin lines, skin cracks and scars, for reparative or plastic surgery, aesthetic dermatology, and for filling up gums in dental treatment. The invention concerns the use of biologically absorbable polymer microspheres or microparticles suspended in a gel. Said suspension is produced either ready-for-use or freeze-dried. The biological absorbability of the microspheres is controlled and enables the production of implants having well defined persistence and deliberately limited to 3 years.

  • PLANT EXTRACTS FOR TREATING SKIN DISEASES

    The invention relates to the utilization of an extract or of extracts, of lipophilic extracts as well as hydrophilic extracts from the fruit of the plant Pandanus conoideus for production of topical preparations for the treatment of diseases of skin and of the mucous membrane in the region of the nose, eyes and/or ears, and in particular for treating of dry skin, neurodermatitis, dermatitis, eczemas, psoriasis, metabolic disorders of the skin, acne, damaged skin, symptoms of skin aging and for smoothing the skin, increasing the skin's hydration and for the treatment and prophylaxis of neurodermatitis, dermatitis, eczemas, and psoriasis.

  • 2alpha-Methyl and 2beta-Methyl Analogs of 19,26-Dinor-1alpha,25-Dihydroxyvitamin D3 and Their Uses

    This invention discloses 2.alpha.-methyl and 2.beta.-methyl analogs of 19,26-dinor-1.alpha.,25-dihydroxyvitamin D.sub.3 and pharmaceutical uses therefor. These compounds exhibit in vitro biological activities evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. These compounds have little, if any, in vivo calcemic activity and therefore may be used to treat autoimmune disorders in humans as well as secondary hyperparathyroidism and renal osteodystrophy.

  • Systems, Models and Methods for Identifying and Evaluating Skin-Active Agents Effective for Treating Dandruff/Seborrheic Dermatitis

    Methods and systems for determining functional relationships between a skin-active agent and a skin condition of interest, and methods and systems for identifying cosmetic agents effective for treatment of dandruff, as well as the use of agents identified by such methods and systems for the preparation of cosmetic compositions, personal care products, or both are provided. Methods for developing in vitro models of skin disease and models for specific skin diseases are also provided.

  • TOPICAL FORMULATIONS COMPRISING A STEROID

    The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

  • ULTRASONIC IMAGING DEVICE AND INFORMATION PROCESSING DEVICE

    Provided is an ultrasonic imaging device that noninvasively measures the stiffness of the cardiac muscle, which is the heart muscle, or intracardiac pressure, which is the blood pressure inside the heart. The ultrasonic imaging device includes: an ultrasonic probe (2) that transmits and receives ultrasonic waves to and from the heart, which is the target organ inside the body; a signal-processing section (15) that processes reflected echo signals received by the ultrasonic probe; a display section (14) that displays the results of signal processing as an image; and an input section (10) for setting a predetermined point on the image displayed on the display section. The signal-processing section (15) includes: a shape-extracting section (152) that perceives information on the shape of the heart from the reflected echo signals; a natural-frequency detecting section (153) that detects the natural frequency of the heart from the reflected echo signals; and a calculating section (154) that calculates the stiffness of the cardiac muscle or the intracardiac pressure, wherein the calculating section (154) accurately calculates the stiffness of the cardiac muscle from the natural frequency of the heart and calculates the intracardiac pressure from the stiffness of the cardiac muscle that has been calculated.

  • Multi-Modality Ultrasound and Radio Frequency System for Imaging Tissue

    This invention provides a dual-modality system for performing characterization and imaging of tissue, tumors, structures, lesions, and ablations under investigation. Specifically, the invention couples ultrasound technology comprising at least two focused ultrasound beams for vibrating target tissues located at the focal point of the ultrasound beams intersection with a radio frequency system for measuring the response of the target tissues. The ultrasound system vibrates the target tissues while the reflected radio frequency energy is transmitted into the target tissues. When reflected, the main carrier tone of the reflected radio frequency energy is cancelled and analysis is performed on the remaining sideband frequencies.

  • ENDOSCOPIC IMAGING DEVICE

    An endoscopic imaging device for endoscopy in a body vessel is disclosed. The device comprises an annular illumination tube comprising an annular illumination fiber for illuminating a body vessel during endoscopy. The device further includes a first imaging tube comprising a first imaging fiber for gross examination and navigation through the body vessel. The first imaging fiber is disposed within the annular illumination tube. The device further comprises a second imaging tube comprising a second imaging fiber for cellular imaging. The second illumination fiber is disposed adjacent the first imaging tube and within the annular illumination tube.

  • COMBINATIONS OF LIQUID FILTRATION MEDIA AND METHODS FOR ENHANCED FILTRATION OF SELECTED WATER CONTAMINANTS

    By sequentially aligning various filtration media and delivery systems, enhanced synergistic reduction of water contaminants is obtained compared to the prior art or separate use of the individual media/filters. Specific filtration media are formulated with proper proportioning and sequencing to enhance the ability to reduce metals that cause staining, odors and bad taste such as iron, copper and manganese. Also disclosed is the reduction of potentially hazardous metal radionuclides metals such as uranium, iodine, cesium, plutonium and radium. Also disclosed is improved removal of heavy metals such as arsenic, lead, chromium, and mercury as well as organic compounds such as halogenated carcinogenic compounds. The present devices and methods remove specific bacteria and their toxins from water to reduce the risk of dermatitis. Thus, the present invention enhances our ability to achieving cleaner and safer water for drinking, swimming, washing, bathing and cooking.

  • DEVICE FOR UV PHOTO-THERAPY

    Skin disorders such as, for example, atopic dermatitis, dyshidrosis, eczema, lichen planus, psoriasis, and vitiligo, are treated by applying high doses of ultraviolet light to diseased regions of a patient's skin. The dosage exceeds 1 MED as determined for the particular patient and may range from about 1 MED to about 20 MED or higher. The ultraviolet light has a wavelength within the range of about 295 nanometers to about 320 nanometers. High doses of ultraviolet light are preferably restricted to diseased tissue areas. A specialized handpiece provides a beam profile especially suitable for application of controlled doses. A specialized delivery device is useful for UV treatment of tissue within the mouth.

  • TREATMENT OF SKIN DISORDERS WITH UV LIGHT

    Skin disorders such as, for example, atopic dermatitis, dyshidrosis, eczema, lichen planus, psoriasis, and vitiligo, are treated by applying high doses of ultraviolet light to diseased regions of a patients skin. The dosage employed exceeds 1 MED, an MED being determined for the particular patient being treated, and may range from about 1 MED to about 20 MED or higher. The ultraviolet light has a wavelength within the range of between about 295 nanometers to about 320 nanometers and preferably is between about 300 nanometers and about 310 nanometers. High doses of ultraviolet light are restricted to diseased tissue areas so as to avoid risk of detrimental side affects in healthy skin, which is more susceptible to damage from UV light. Cooling the skin prior to and/or while exposing the skin to the UV light can be used to minimize tissue damage resulting from exposure to the UV light. Higher doses of UV light can therefore be employed without injurious affects.

  • ZINC OXIDE/ACID CONTAINING COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING ENZYMATIC IRRITATION

    Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably zinc oxide in combination with an acid so as to release a specified divalent cation, i.e., zinc.

  • DIVALENT CATION/ANION PAIR CONTAINING COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING ENZYMATIC IRRITATION

    Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a divalent cation/anion pair.

  • DIVALENT CATION CONTAINING COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING ENZYMATIC IRRITATION

    Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a divalent cation.

  • DIVALENT CATION/TALC CONTAINING COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING ENZYMATIC IRRITATION

    Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a specified divalent cation, i.e., magnesium, in combination with talc.

  • GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHDOS OF DETECTION AND USES THEREOF

    The invention provides skin-protecting and penetrating, easy-to-administer base and active agent-containing compositions, such as those including hydrocortisone, for treating the skin of mammals for different dermatologic disorders. This is effected by topically administering effective amounts of the compositions thereto in forms that address the skin and mucosa of the mouth and lips, and the rest of the body. Additionally, an optional flavoring addition to these products affords significantly better tasting, and less bitter, compositions, allowing a more pleasant experience and better compliance by patients. The compositions include a unique formulation of FANCOL VB, Natunola Castor 1023, Finsolv TN, bees wax and, optionally, one or a plurality of plant or plant seed oils, fatty alcohols, fats and flavorings, in desirable weight percents thereof, in various forms, and preferably in a form of a solid roll-on stick in a variety of sizes and of a jar or pot.

  • COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH

    Provided are compositions comprising alkylating agents, including nitrogen mustards, that are suitable for topical use, and methods for treating skin disorders comprising topically administering the compositions.

  • METHOD OF USE OF STABILIZED NON-PLANT-DERIVED GROWTH FACTOR IN SKIN CARE

    Cosmetic and dermatologic compositions for skin care, containing a non-plant derived growth factor, purified from a host organisms or host cells such as bacterial, yeast, or animal cells, including insect cells, or a mixture of growth factors in purified form, for use in topical therapeutics, dermatology and cosmetics. Importantly this invention provides stabilized, safer growth factors available for use for cosmetic and topical treatment. Preferred composition comprises a non-plant derived growth factor and hyaluronic acid. The skin-care/dermatological compositions with stabilized growth factor do not carry the risk of unwanted breakdown products and the resulting loss of activity of the composition.

  • RETINAL CYCLODEXTRIN ACETALS AND HEMIACETALS FOR TREATING SKIN COMPLEXION DISORDER

    The present invention discloses certain polyene cyclodextrin acetals and hemiacetals that are effective in providing skin clarification, which is useful for the treatment of acne, and skin disfigurements and skin darkening resulting from acne; skin darkening from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial and DNA dysfunction; age spots; loss of cellular antioxidants; skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines, oxidation, damage from radiation, damage from free radicals, and damage from UV; dry skin; xerosis; ichthyosis; dandruff; brownish spots; keratoses; melasma; lentigines; liver spots; skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin, and blemishes; oily skin; warts; eczema; pruritic skin; psoriasis; inflammatory dermatoses; topical inflammation; disturbed keratinization; scalp dryness, and combinations thereof.

  • SILICONE-BASED COMPOSITION FOR SKIN TREATMENT

    The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients.

  • ASTRAGALUS SEED EXTRACT SOLUTION AND ITS USE FOR TREATING SKIN DISORDERS AND CONDITIONS

    An aqueous Astragalus seed extract solution prepared by a method including soaking dried seeds of Astragalus seed in an aqueous solvent to form a suspension, boiling the suspension for at least 30 minutes, and filtering the suspension so as to obtain the Astragalus seed aqueous extract solution, the weight ratio of the dried seeds of Astragalus seed to the extract solution being 1:100 to 75:100.

  • TOPICAL MIXTURE AND METHOD FOR DERMAL APPLICATION TO REMOVE EXCESS IRON AND OTHER HEAVY METALS FROM CELLULAR TISSUE

    A topical mixture intended to reduce undesirable Iron levels in the cells to optimize Mitochondrial functioning. A method of reducing undesirable levels of Iron in the cells to optimize Mitochondrial functioning.

  • HEXAPEPTIDE WITH IMPROVED ACTIVITY IN THE REPAIR OF CELLULAR DNA OF DERMAL CELLS

    The present invention relates to a compound having a structure selected from: Ac-Nle-Glu-His-D-Phe-Arg-Trp-NH.sub.2 (SEQ ID NO: 1); or Ac-Nle-Gln-His-D-Phe-Arg-Trp-NH.sub.2 (SEQ ID NO: 2) or a pharmaceutically acceptable salt thereof. The compound of the salt thereof are particularly useful for the repair or prevention of damage of cellular DNA of dermal (skin) cells following UV irradiation in a mammal.

  • NOVEL FORMULATIONS FOR DERMAL, TRANSDERMAL AND MUCOSAL USE

    A dermal, transdermal and/or mucosal formulation for topical application on skin, comprising an active pharmaceutical ingredient and a pharmaceutically acceptable solvent, and an anti-solvent; wherein the active pharmaceutical ingredient is soluble in the solvent in the absence of the anti-solvent, and wherein the active pharmaceutical ingredient is substantially in the solid state in the presence of the anti-solvent. A method for increasing the stability of an active pharmaceutical ingredient.

  • INJECTABLE MICROSPHERES FOR DERMAL AUGMENTATION AND TISSUE BULKING

    The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.

  • DERMAL COMPOSITION COMPRISING POLYMERIC REVERSED MICELLE, AND METHOD FOR PRODUCING SAME

    The present invention provides a dermal composition comprising a polymeric reversed micelle that allows a water-soluble drug to be efficiently encapsulated and that is superior in percutaneous absorptiveness and very safe, and provides a method that can produce the composition in simple steps. The dermal composition comprises a polymeric reversed micelle composed of an amphipathic polymer having a hydrophilic segment and a hydrophobic segment, wherein the polymeric reversed micelle has a configuration in which the hydrophilic segment is the core and the hydrophobic segment is the shell, and a water-soluble drug is encapsulated therein. The composition can be produced by blending an oil phase comprising the amphipathic polymer in an oily base agent with an aqueous phase comprising the water-soluble drug in an aqueous solvent, or by blending an oily base agent with an aqueous phase comprising the amphipathic polymer and the water-soluble drug in an aqueous solvent.

  • EXTERNALLY-USED DRUG FOR TREATING SKIN DISORDER AND METHOD FOR PRODUCING SAME

    An external medicine of the present invention includes a gel composition or an ointment composition, each of which contains sirolimus and/or a derivative thereof. Accordingly, provided is an external medicine which enables sirolimus, in an amount sufficient to treat a skin disease, to be absorbed into an affected part without causing a side effect.

  • TAPE STRIPPING METHODS FOR ANALYSIS OF SKIN DISEASE AND PATHOLOGICAL SKIN STATE

    The present invention provides non-invasive methods for detecting, monitoring, and diagnosing skin disease and pathological skin states such as irritated skin and psoriasis. The methods include using tape stripping to analyze expression in epidermal samples, of one or more skin markers. In illustrative examples, the tape stripping is performed using pliable tape that has a rubber adhesive. Furthermore, the present invention provides methods for predicting and monitoring response to therapy for a skin disease, such as psoriasis or dermatitis. Finally, the methods can include the use of a microarray.

  • DERMATOLOGICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ROSACEA, OF COUPEROSE OR OF SKIN WHICH EXHIBITS DIFFUSE REDNESS OR SMALL DILATED VESSELS

    The invention relates to a dermatological composition for the prevention and/or treatment of rosacea, of couperose or of skin which exhibits diffuse redness or small dilated vessels, characterized in that it contains: -at least one interference pigment comprising titanium dioxide-coated mica, transmitting a colour complementary to red; -at least one sunscreen that is active in the UVA and UVB ranges; -one or more soothing and/or moisturizing active ingredients; and -the rest as dermatologically acceptable excipient(s) necessary for formulating said composition.

  • SKIN CARE COMPOSITION

    The present invention relates to a composition for enhancing the overall quality of the skin and for treating aging skin, comprising from 0.05 to 5.0% by weight of a depolymerized hydroxypropyl guar having MS between 1.5 and 3.5, in a cosmetic or pharmaceutical acceptable carrier.

  • NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR

    Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPAR.alpha. and PPAR.gamma. activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

  • NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR

    Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPAR.alpha. and PPAR.gamma. activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

  • EXTERNAL SKIN PREPARATION AND PRODUCTION METHOD OF SAME

    Provided are: an external skin preparation that contains a whitening agent in the form of a resorcinol derivative and causes minimal irritation of the skin, and a production method thereof. The external skin preparation contains 0.1% by weight to 5% by weight of the resorcinol derivative and 0.01% by weight to 5% by weight of the ascorbyl 2-phosphate-6-palmitate.

  • SYSTEMS AND METHODS FOR TREATMENT OF ANDROGENETIC SKIN CONDITIONS BY MICROBIAL ORGANISMS

    A specific naturally occurring or genetically modified bacterial strain can be introduced into the hair follicle of patients suffering from androgenetic alopecia as to reduce the bioavailable extracellular testosterone and hence reduce the effect of androgens on the hair follicle.

  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES

    Provided herein are chemical matrices, compositions, methods and devices for the treatment of skin diseases and disorders in an individual. Described herein are non-homogenous chemical matrices and compositions comprising an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, optionally, at least one pharmaceutical agent, wherein the alcohol is distributed within the chemical matrix as a microbubble. Additionally, methods are described for the use of said chemical matrices and compositions for the treatment of skin diseases and disorders.